A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma
← catalyst calendarNCT06392477 · readout in 520 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
96estimated
Sites
16
Countries
Australia, Serbia, Singapore +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-08 | actual | When the study began enrolling |
| Primary completion | 2028-01-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-11 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- B-cell Non Hodgkin Lymphoma
Intervention
- Drug: SAR448501 — also filed as DR-0201
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse event (TEAE)
measured Baseline to 28 days post last dose
Potential pharmacologically optimized dose/regimen(s) of SAR448501 / DR-0201 in participants with R/R B-NHL
measured Cycle 1 (Day 1 to Day 28)
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed